• Active, not recruiting

NCT04000282: Phase 1: First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory MM

NCT04000282: Phase 1: First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma


SAR442085

NCT04000282: Phase 1: First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma


Primary Objectives:

Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B

Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085 at the RP2D in patients with RRMM


Sponsor

Sanofi

 

ClinicalTrials.gov Identifier: NCT04000282

Official Title: An Open-label, First-in-human, Single Agent, Dose-escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442085 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

First Posted : June 27, 2019

Click here for details on ClinicalTrials.gov

 

SAR 442085

Anti-CD38 Monoclonal Antibody SAR442085 (Code C166376)

Anti-CD38 Monoclonal Antibody SAR442085

SAR 442085

SAR-442085

SAR442085

 

Drug: SAR442085

 

Location

United States, California

United States, Massachusetts

United States, Minnesota

United States, North Carolina

United States, Wisconsin

Czechia

France

Greece

Spain

Taiwan




Posts Archive